ATM: Time to Withdraw?

therapies targeting DNA repair pathways in prostate cancer, patients with BRCA1 and BRCA2 mutations, failure of PARP inhibitors leading to psa reductions, how ATM differs from BRCA1 and BRCA2, atm’s function, treatment solutions for patients with ATM mutations outside of PARP inhibition, dna damage sensors

Read the full article here

Related Articles